Agilent Technologies Acquires Digital Pathology Software Firm Proscia for $240M
Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences customers, the companies announced.1
By Victoria Shi · AI Funding Reporter Nov 9, 2026

Under the terms of the deal, which closed on November 4, 2026, Agilent made a cash payment of $240 million, with up to an additional $30 million contingent on future performance milestones, according to multiple press reports. Philadelphia-based Proscia is now part of Agilent's Life Sciences and Diagnostics Markets Group.2
Proscia, founded in 2014, provides a vendor-agnostic software platform that has received FDA 510(k) clearance for primary diagnosis. The company reports that it serves 16 of the top 20 pharmaceutical companies and was named the 2026 Global Best in KLAS for Digital Pathology in Europe. One report noted Proscia had previously raised a total of $130 million in funding.2,3
Santa Clara, Calif.-based Agilent provides pathology instruments and reagents. The acquisition follows a multiyear distribution agreement from September 2022, under which Agilent offered Proscia's software with its own products, according to R&D World Online.
In a press release, the companies stated the combination aims to advance AI-powered pathology workflows and accelerate drug discovery. Agilent said the deal strengthens its position in what it estimates to be a $5 billion digital pathology market by adding a recurring-revenue software business.2
"Proscia's talented team and leading vendor-agnostic digital-pathology platform enhance our ability to support customers across clinical diagnostics, biopharma, and life-sciences research," Agilent President and CEO Padraig McDonnell said in a statement.